Evidence map›Paper›PMID 37648911›Full record

ArticleJournal of neurology2023

Volumetric changes and clinical trajectories in Parkinson's disease: a prospective multicentric study.

Ana Marques, Elise Macias, Bruno Pereira, Elodie Durand, Carine Chassain, Tiphaine Vidal, Luc Defebvre, Nicolas Carriere, Valerie Fraix, Elena Moro and 24 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors at 12 institutions in 3 countries.

Ana MarquesUniversity Clermont Auvergne, CNRS, Clermont Auvergne INP, IGCNC, Institute Pascal, Clermont-Ferrand, France. ar_marques@chu-clermontferrand.fr.ORCID http://orcid.org/0000-0003-2428-4899
Elise MaciasUniversity Clermont Auvergne, CNRS, Clermont Auvergne INP, IGCNC, Institute Pascal, Clermont-Ferrand, France.
Bruno PereiraClermont-Ferrand University Hospital, Biostatistics Unit (DRCI), Clermont-Ferrand, France.
Elodie DurandUniversity Clermont Auvergne, CNRS, Clermont Auvergne INP, IGCNC, Institute Pascal, Clermont-Ferrand, France.
Carine ChassainUniversity Clermont Auvergne, CNRS, Clermont Auvergne INP, IGCNC, Institute Pascal, Clermont-Ferrand, France.
Tiphaine VidalUniversity Clermont Auvergne, CNRS, Clermont Auvergne INP, IGCNC, Institute Pascal, Clermont-Ferrand, France.
Luc DefebvreDepartment of Movement Disorder and NS-PARK/FCRIN Network, Inserm 1172, University of Lille, Lille, France.
Nicolas CarriereDepartment of Movement Disorder and NS-PARK/FCRIN Network, Inserm 1172, University of Lille, Lille, France.
Valerie FraixUniversité Grenoble Alpes, CHU de Grenoble, Service de Neurologie, Grenoble Institute of Neuroscience, and NS-PARK/FCRIN Network, Grenoble, France.
Elena MoroUniversité Grenoble Alpes, CHU de Grenoble, Service de Neurologie, Grenoble Institute of Neuroscience, and NS-PARK/FCRIN Network, Grenoble, France.
Stéphane ThoboisCNRS, Institut des Sciences Cognitives Marc Jeannerod, UMR 5229 CNRS, Lyon, France.
Elise MetereauCNRS, Institut des Sciences Cognitives Marc Jeannerod, UMR 5229 CNRS, Lyon, France.
Graziella MangoneDépartement de Neurologie and NS-PARK/FCRIN Network, Sorbonne Université; Institut du Cerveau-ICM, Assistance Publique Hôpitaux de Paris; Inserm 1127, CNRS 7225, CIC Neurosciences, Hôpital Pitié-Salpêtrière, Paris, France.
Marie VidailhetDépartement de Neurologie and NS-PARK/FCRIN Network, Sorbonne Université; Institut du Cerveau-ICM, Assistance Publique Hôpitaux de Paris; Inserm 1127, CNRS 7225, CIC Neurosciences, Hôpital Pitié-Salpêtrière, Paris, France.
Jean-Christophe CorvolDépartement de Neurologie and NS-PARK/FCRIN Network, Sorbonne Université; Institut du Cerveau-ICM, Assistance Publique Hôpitaux de Paris; Inserm 1127, CNRS 7225, CIC Neurosciences, Hôpital Pitié-Salpêtrière, Paris, France.
Stéphane LehéricyDépartement de Neuroradiologie and NS-PARK/FCRIN Network, Sorbonne Université; Institut du Cerveau-ICM, Assistance Publique Hôpitaux de Paris; Inserm 1127, CNRS 7225; Hôpital Pitié-Salpêtrière, Paris, France.
Nicolas Menjot de ChampfleurDepartment of Neuroradiology, Montpellier University Hospital Center, Gui de Chauliac Hospital, Montpellier, France.
Christian GenyDepartment of Geriatrics and NS-PARK/FCRIN Network, Montpellier University Hospital, Montpellier University, Montpellier, France.
Umberto SpampinatoService de Neurologie-Maladies Neurodégénératives and NS-PARK/FCRIN Network, CHU Bordeaux, 33000, Bordeaux, France.
Wassilios G MeissnerService de Neurologie-Maladies Neurodégénératives and NS-PARK/FCRIN Network, CHU Bordeaux, 33000, Bordeaux, France.
Solène FrismandDepartment of Neurology and NS-PARK/FCRIN Network, Nancy University Hospital Center, Nancy, France.
Emmanuelle SchmittDepartment of Neuroradiology, Nancy University Hospital Center, Nancy, France.
Anne Doé de MaindrevilleDepartment of Neurology and NS-PARK/FCRIN Network, Hôpital Maison Blanche, Reims, France.
Christophe PortefaixDepartment of Radiology, Hôpital Maison Blanche, Reims, France.
Philippe RemyCentre Expert Parkinson and NS-PARK/FCRIN Network, CHU Henri Mondor; AP-HP et Equipe Neuropsychologie Interventionnelle, INSERM-IMRB, Faculté de Santé, Université Paris-Est Créteil et Ecole Normale Supérieure Paris Sorbonne Université, Créteil, France.
Gilles FénelonCentre Expert Parkinson and NS-PARK/FCRIN Network, CHU Henri Mondor; AP-HP et Equipe Neuropsychologie Interventionnelle, INSERM-IMRB, Faculté de Santé, Université Paris-Est Créteil et Ecole Normale Supérieure Paris Sorbonne Université, Créteil, France.
Jean Luc HouetoINSERM, CHU de Poitiers, Université de Poitiers, Centre d'Investigation Clinique CIC1402; Service de Neurologie and NS-PARK/FCRIN Network, Poitiers, France.
Olivier ColinINSERM, CHU de Poitiers, Université de Poitiers, Centre d'Investigation Clinique CIC1402; Service de Neurologie and NS-PARK/FCRIN Network, CH Brive la Gaillarde, Poitiers, France.
Olivier RascolCentre Expert Parkinson, Départements de Pharmacologie Clinique et Neurosciences, Centre d'Investigation Clinique CIC 1436, UMR 1214 TONIC, NeuroToul and NS-PARK/FCRIN Network, INSERM, CHU de Toulouse et Université de Toulouse3, Toulouse, France.
Patrice PeranToNIC, Toulouse NeuroImaging Center, Université de Toulouse, INSERM, UPS, Toulouse, France.
Jean-Marie BonnyINRAE, UR QuaPA, 63122, Saint-Genès-Champanelle, France.
Maria Livia FantiniUniversity Clermont Auvergne, CNRS, Clermont Auvergne INP, IGCNC, Institute Pascal, Clermont-Ferrand, France.
Franck DurifUniversity Clermont Auvergne, CNRS, Clermont Auvergne INP, IGCNC, Institute Pascal, Clermont-Ferrand, France.
R2* Study Group
Centre National de la Recherche Scientifique · FRInserm · FRCentre Hospitalier Universitaire de Grenoble · FRUniversité Claude Bernard Lyon 1 · FRUniversité de Montpellier · FRCentre de Recherche en Sciences et Technologies de l'Information et de la Communication · FRCentre Hospitalier Régional et Universitaire de Nancy · FRCentre Hospitalier Universitaire de Clermont-Ferrand · FRCentre Hospitalier Universitaire de Reims · FRFrench Clinical Research Infrastructure Network · FRInstitut National de la Recherche Agronomique · MAUniversité Toulouse III - Paul Sabatier · FR

Funding

Association France Parkinson GAO-2013Clinical research Hospital Program PHRC-I 2016
6 · The paper itself

Abstract

backgroundLongitudinal measures of structural brain changes using MRI in relation to clinical features and progression patterns in PD have been assessed in previous studies, but few were conducted in well-defined and large cohorts, including prospective clinical assessments of both motor and non-motor symptoms.

objectiveWe aimed to identify brain volumetric changes characterizing PD patients, and determine whether regional brain volumetric characteristics at baseline can predict motor, psycho-behavioral and cognitive evolution at one year in a prospective cohort of PD patients.

methodsIn this multicentric 1 year longitudinal study, PD patients and healthy controls from the MPI-R2* cohort were assessed for demographical, clinical and brain volumetric characteristics. Distinct subgroups of PD patients according to motor, cognitive and psycho-behavioral evolution were identified at the end of follow-up.

resultsOne hundred and fifty PD patients and 73 control subjects were included in our analysis. Over one year, there was no significant difference in volume variations between PD and control subjects, regardless of the brain region considered. However, we observed a reduction in posterior cingulate cortex volume at baseline in PD patients with motor deterioration at one year (p = 0.017). We also observed a bilateral reduction of the volume of the amygdala (p = 0.015 and p = 0.041) and hippocampus (p = 0.015 and p = 0.053) at baseline in patients with psycho-behavioral deterioration, regardless of age, dopaminergic treatment and center.

conclusionBrain volumetric characteristics at baseline may predict clinical trajectories at 1 year in PD as posterior cingulate cortex atrophy was associated with motor decline, while amygdala and hippocampus atrophy were associated with psycho-behavioral decline.

Indexed as

Parkinson DiseaseAtrophyBrainHumansLongitudinal StudiesProspective StudiesBrain atrophyClinical progressionLongitudinal studyParkinson’s diseaseVolumetric changes

Identifiers

PMID37648911
OpenAlexW4386305014

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.